Preclinical studies showed that VX-944 was 3 to 40 times more potent than MPA in acute myeloid leukemia (AML) cell lines and was active against both FLT3 mutated and unmutated cells [139]. The gene discussed is FLT3; the disease is acute myeloid leukemia.